Bio-Thera Reports Positive Bevacizumab Results
Avastin Rival Is Firm’s Second Biosimilar With Positive Phase III Outcome
Executive Summary
China’s Bio-Thera Solutions has reported positive Phase III results for its proposed bevacizumab biosimilar rival to Avastin.
You may also be interested in...
Bio-Thera’s Bevacizumab US Action Date Passes Without Approval
Bio-Thera Solutions had been hoping to become the first Chinese biosimilars developer to win an FDA approval, for its BAT1706 bevacizumab candidate. However, the announced FDA action date for the application has come and gone with no word from the company or regulator.
Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date
China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.
Biomm Backs Bio-Thera’s Brazilian Bevacizumab
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.